Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cerebral atrophy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44300   clinical trials with a EudraCT protocol, of which   7354   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    47 result(s) found for: Cerebral atrophy. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2014-002118-21 Sponsor Protocol Number: CPZOL Start Date*: 2017-03-17
    Sponsor Name:Randers Regional Hospital
    Full Title: Zoledronate against fractures in children with cerebral palsy
    Medical condition: cerebral palsy, osteopenia, fracture
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10049088 Osteopenia PT
    15.1 100000005035 10034157 Pathological fractures and complications HLT
    20.0 10042613 - Surgical and medical procedures 10049904 Osteoporosis prophylaxis PT
    20.0 100000012650 10021740 Infantile cerebral palsy LLT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10006002 Bone pain PT
    20.0 100000018618 10013522 Disuse osteoporosis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-002295-40 Sponsor Protocol Number: 08-06-2018-paracet Start Date*: 2018-09-11
    Sponsor Name:Copenhagen Neuromuscular Center
    Full Title: Pharmacokinetics and safety of treatment with paracetamol in children and adults with spinal muscular atrophy and cerebral palsy
    Medical condition: Spinal muscular atrophy type II (SMA II) Cerebral palsy (CP)
    Disease:
    Population Age: Children, Under 18, Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-000956-12 Sponsor Protocol Number: 277HV101 Start Date*: Information not available in EudraCT
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Randomized, Blinded, Placebo-Controlled, Phase 1 Single Ascending Dose Study in Healthy Adult Male Volunteers and an Open-Label Multiple Ascending Dose Study in Pediatric SMA Participants Previou...
    Medical condition: Spinal muscular atrophy
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10041582 Spinal muscular atrophy PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) DE (Ongoing) PT (Prematurely Ended) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004634-41 Sponsor Protocol Number: IIBSP-FPI-2019-108 Start Date*: 2021-08-25
    Sponsor Name:Institut de Recerca HSCSP
    Full Title: Study of the positron emission tomography (PET) tracer for tau 18F-PI-2620 in individuals with Down syndrome
    Medical condition: Taupathies
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-001949-42 Sponsor Protocol Number: BRD50 Start Date*: 2005-09-08
    Sponsor Name:University College London
    Full Title: A randomised controlled trial of neuroprotection with lamotrigine in secondary progressive multiple sclerosis
    Medical condition: Multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-018157-23 Sponsor Protocol Number: D0490C00014 Start Date*: 2010-11-30
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase IIa, Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel Group 12-Month Treatment, Adaptive Design Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics ...
    Medical condition: Multiple system atrophy
    Disease: Version SOC Term Classification Code Term Level
    12.1 10064060 Multiple system atrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000928-18 Sponsor Protocol Number: PROMESA Start Date*: 2013-11-21
    Sponsor Name:Hospital of the Ludwig-Maximilians-University of Munich
    Full Title: Double blind, randomised, prospective placebo controlled parallel group phase III study to investigate the Effect of EGCG supplementation on disease progression of patients with Multiple System Atr...
    Medical condition: Progression of patients with Multiple System Atrophy (MSA)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003284-38 Sponsor Protocol Number: EVG001SAH Start Date*: 2016-02-15
    Sponsor Name:Evgen Pharma plc
    Full Title: SFX-01 AFTER SUBARACHNOID HAEMORRHAGE
    Medical condition: Subarachnoid Haemorrhage
    Disease: Version SOC Term Classification Code Term Level
    20.1 10022117 - Injury, poisoning and procedural complications 10042316 Subarachnoid haemorrhage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-000621-12 Sponsor Protocol Number: ISIS396443-CS3A Start Date*: 2017-02-15
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: A Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients With Infantile-Onset Spinal Muscular Atrophy
    Medical condition: Spinal Muscular Atrophy (SMA)
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-002805-13 Sponsor Protocol Number: LTF-304 Start Date*: 2015-11-27
    Sponsor Name:bluebird bio, Inc
    Full Title: Longterm Follow-up of Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product
    Medical condition: Cerebral Adrenoleukodystrophy (CALD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10051260 Adrenoleukodystrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003008-30 Sponsor Protocol Number: 16/0730 Start Date*: 2020-07-01
    Sponsor Name:University College London
    Full Title: A double-blind, randomised, placebo-controlled single-site study of high dose simvastatin treatment for secondary progressive multiple sclerosis: impact on vascular perfusion and oxidative damage
    Medical condition: Multiple Sclerosis (Secondary Progressive)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10052785 Multiple sclerosis acute and progressive HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-001953-10 Sponsor Protocol Number: ALD-102 Start Date*: 2013-12-13
    Sponsor Name:bluebird bio, Inc.
    Full Title: A phase 2/3 study of the efficacy and safety of hematopoietic stem cells transduced with Lenti D lentiviral vector for the treatment of cerebral adrenoleukodystrophy (CALD)
    Medical condition: Cerebral Adrenoleukodystrophy (CALD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10051260 Adrenoleukodystrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) DE (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-003484-30 Sponsor Protocol Number: CFTY720DES03 Start Date*: 2011-10-26
    Sponsor Name:Novartis Farmacéutica S.A.
    Full Title: A multi-centre, open-label, non-randomised, parallel group clinical trial to assess the efficacy of fingolimod in naïve patients versus fingolimod in patients previously treated with interferons or...
    Medical condition: Multiple Sclerosis relapsing-remitting course
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-005262-39 Sponsor Protocol Number: 2006-2209 Start Date*: 2007-05-30
    Sponsor Name:Charité-Universitätsmedizin Berlin
    Full Title: Flupirtin as Oral Treatment in MS
    Medical condition: Relapsing-remitting multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-004733-17 Sponsor Protocol Number: XAMNPEAP2019 Start Date*: 2020-02-25
    Sponsor Name:Aurora Pujol Onofre
    Full Title: Effect of plasma exchange by albumin replacement in Adrenomyeloneuropathy: unicentric, single arm, proof of concept trial
    Medical condition: Adrenomyeloneuropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10069075 Adrenomyeloneuropathy without cerebral involvement LLT
    Population Age: Adults Gender: Male
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-012569-79 Sponsor Protocol Number: BAY94-9172/14595 Start Date*: 2012-01-09
    Sponsor Name:Bayer AG
    Full Title: An open-label, non-randomized study to evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detection/exclusion of cerebral ß-amyloid when com...
    Medical condition: Detection/Exclusion of cerebral ß-amyloid. To determine the sensitivity and specificity of the visual assessment of regional tracer uptake in the BAY 94-9172 PET images compared to histological ...
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-000654-59 Sponsor Protocol Number: MT-2-02 Start Date*: 2019-06-25
    Sponsor Name:Minoryx Therapeutics S.L.
    Full Title: An exploratory, open-label, multicenter study in male pediatric patients with cerebral X-linked Adrenoleukodystrophie (cALD) to assess the effect of MIN-102 treatment on the progression of cerebral...
    Medical condition: Cerebral X-linked Adrenoleukodystrophy (cALD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10051260 Adrenoleukodystrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: ES (Ongoing) DE (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001145-14 Sponsor Protocol Number: ALD-104 Start Date*: 2019-04-17
    Sponsor Name:bluebird bio, Inc.
    Full Title: A Phase 3 Study of Lenti-D Drug Product After Myeloablative Conditioning Using Busulfan and Fludarabine in Subjects ≤17 Years of Age With Cerebral Adrenoleukodystrophy (CALD)
    Medical condition: Cerebral Adrenoleukodystrophy (CALD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10051260 Adrenoleukodystrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Ongoing) DE (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000422-38 Sponsor Protocol Number: PET_imaging_of_Tau Start Date*: 2014-09-19
    Sponsor Name:Skåne University Hospital, Region Skåne
    Full Title: An open-label study evaluating the diagnostic accuracy of [18F]-AV-1451 PET to detect and distinguish neurodegenerative disorders characterized by cerebral accumulation of tau
    Medical condition: Neurodegenerative disorders with Tau-pathology; including Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, corticobasal degeneration and important differential diagnost...
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10001897 Alzheimer's disease (incl subtypes) HLT
    17.0 10029205 - Nervous system disorders 10053643 Neurodegenerative disorder PT
    17.0 10029205 - Nervous system disorders 10009846 Cognitive impairment LLT
    17.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    17.0 10029205 - Nervous system disorders 10012285 Dementia due to Pick's disease LLT
    17.0 10029205 - Nervous system disorders 10012267 Dementia PT
    17.0 10029205 - Nervous system disorders 10067889 Dementia with Lewy bodies PT
    17.0 10029205 - Nervous system disorders 10036813 Progressive supranuclear palsy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002256-42 Sponsor Protocol Number: 311741 Start Date*: 2009-06-24
    Sponsor Name:Bayer Schering Pharma AG
    Full Title: An open-label, non-randomized, multi-center study to optimize image assessment and evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) for detection/excl...
    Medical condition: Probable Alzheimer Disease patients compared to Healthy Volunteers. The clinical diagnosis - in Part A made by the investigator, in Part B established by an independent consensus panel of experts...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA